智通财经APP获悉，4月17日，礼来(LLY.US)宣布III期ACHIEVE-1研究取得积极结果，该研究评估了orforglipron与安慰剂相比在饮食和运动单独控制不佳的2型糖尿病成人中的安全性和疗效。Orforglipron是首个成功完成III期研究的口服小分子胰高血糖素样肽-1(GLP-1)受体激动剂，服用时无需食物和水限制。礼来表示未来该药如果获批，将对其能够在全球范围内推出orforglipron且不受供应限制充满信心。
在ACHIEVE-1研究中，orforglipron达到了与安慰剂相比在40周时A1C降低更优的主要终点，从8.0%的基线平均降低A1C 1.3%至1.6%，使用疗效估计量。在一个关键的次要终点中，超过65%接受最高剂量orforglipron治疗的受试者者实现了A1C小于或等于6.5%，低于美国糖尿病协会(ADA)定义的糖尿病阈值。在另一个关键的次要终点中，接受orforglipron治疗的受试者在最高剂量下平均减重16.0磅(7.9%)。鉴于受试者在研究结束时尚未达到体重平台期，可能表明尚未实现完全减重。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.